Article title: Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin

Journal name: International Journal of Health Policy and Management (IJHPM)

Authors' information: Boya Zhao^{1,2}, Jing Wu^{1,2}*

¹School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.

²Center for Social Science Survey and Data, Tianjin University, Tianjin, China.

*Correspondence to: Jing Wu, Email: jingwu@tju.edu.cn

Citation: Zhao B, Wu J. Impact of China's national volume-based procurement on drug procurement price, volume, and expenditure: an interrupted time series analysis in Tianjin. Int J Health Policy Manag. 2023;12:7724. doi:10.34172/ijhpm.2023.7724

Supplementary file 2. Supplementary Figures of Subgroup Analysis Results (Figure S2-S7).

Main Content:

Figure S2 (Page 2). Subgroup Analysis: Procurement Price of NVBP-covered Drugs before and after the Pilot NVBP

Figure S3 (Page 3). Subgroup Analysis: Procurement Price of Alternative Drugs before and after the Pilot NVBP

Figure S4 (Page 4). Subgroup Analysis: Procurement Volume of Bid-winning, Non-winning, and NVBP covered Drugs before and after the Pilot NVBP

Figure S5 (Page 5). Subgroup Analysis: Procurement Volume of Alternative Drugs before and after the Pilot NVBP

Figure S6 (Page 6). Subgroup Analysis: Procurement Expenditure of Bid-winning, Non-winning, and NVBP covered Drugs before and after the Pilot NVBP

Figure S7 (Page 7). Subgroup Analysis: Procurement Expenditure of Alternative Drugs before and after the Pilot NVBP

Note: The testing results of autocorrelation and stationary series are available by contacting the authors.




Figure S2. Subgroup Analyses: Procurement Price of NVBP-covered Drugs before and after the Pilot NVBP




Figure S3. Subgroup Analyses: Procurement Price of Alternative Drugs before and after the Pilot NVBP




Figure S4. Subgroup Analyses: Procurement Volume of Bid-winning, Non-winning, and NVBP covered Drugs before and after the Pilot NVBP




Figure S5. Subgroup Analyses: Procurement Volume of Alternative Drugs before and after the Pilot NVBP




Figure S6. Subgroup Analyses: Procurement Expenditure of Bid-winning, Non-winning, and NVBP covered Drugs before and after the Pilot NVBP




Figure S7. Subgroup Analyses: Procurement Expenditure of Alternative Drugs before and after the Pilot NVBP